Treatment News : Worsening Depression in Four Patients on Isentress

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 2, 2008

Worsening Depression in Four Patients on Isentress

Four patients who switched to a regimen containing Isentress (raltegravir) had a temporary worsening of preexisting depression, according to a letter in the September 12 issue of AIDS that was reported by

The safety and efficacy results of several clinical trials of Isentress, Merck’s HIV integrase inhibitor, have been published in journals and presented at medical conferences during the past two years. Thus far, no psychiatric side effects from Isentress have been reported in those clinical trials. Because most early studies of new drugs exclude people with serious underlying psychiatric problems, however, no data have been published on the use of Isentress in people being treated for depression and other mental illnesses.

Marianne Harris, MD, and her colleagues from the AIDS Research Program at St. Paul’s Hospital in Vancouver, Canada, report on four cases of people living with HIV, who had sudden and significant worsening of depression for at least one month after starting Isentress. All four patients were men, and ranged in age from 40 to 55. Each had a history of significant clinical depression, and all were taking medication to treat their depression at the time that they started Isentress.

In each case, the men experienced a sudden onset of serious depression in the first few weeks after starting Isentress. One man’s depression was so severe that he needed to be hospitalized. The men’s health care providers made adjustments to their psychiatric medication, and the depressive symptoms in each man then improved within about 60 days. All the men remained on Isentress during this period.

Dr. Harris’s team claims that they have ruled out other potential causes of the depressive symptoms and feels confident that Isentress was the cause. The authors suggest that there may be some kind of drug interaction between Isentress and psychiatric medications, though no known mechanism has been identified. They encourage health care providers of HIV-positive people being treated for serious mental illness to use caution when initiating treatment with Isentress.

Search: Isentress, raltegravir, depression, mental illness, Marianne Harris, St. Paul's Hospital

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (6 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.